Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $244.73 | 6 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $187.82 | 3 | $0 (2020) |
| Abbott Laboratories | $21.81 | 1 | $0 (2022) |
| Celgene Corporation | $20.29 | 1 | $0 (2017) |
| Lilly USA, LLC | $14.81 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $14.81 | 1 | Lilly USA, LLC ($14.81) |
| 2022 | $21.81 | 1 | Abbott Laboratories ($21.81) |
| 2020 | $126.86 | 2 | GlaxoSmithKline, LLC. ($126.86) |
| 2019 | $60.96 | 1 | GlaxoSmithKline, LLC. ($60.96) |
| 2017 | $20.29 | 1 | Celgene Corporation ($20.29) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Diabetes | ||||||
| 12/09/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Diabetes Care | ||||||
| 10/28/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: RESPIRATORY | ||||||
| 07/27/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $1.86 | General |
| Category: RESPIRATORY | ||||||
| 09/10/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $60.96 | General |
| Category: RESPIRATORY | ||||||
| 01/12/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,531 | 2,285 | $278,191 | $156,973 |
| 2022 | 19 | 1,578 | 3,538 | $229,797 | $146,590 |
| 2021 | 18 | 1,670 | 3,505 | $240,971 | $155,545 |
| 2020 | 29 | 1,884 | 3,510 | $236,202 | $143,541 |
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 2 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 183 | 276 | $38,640 | $21,979 | 56.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 31 | 37 | $10,545 | $8,050 | 76.3% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 217 | 219 | $7,665 | $6,927 | 90.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 217 | 219 | $6,570 | $6,121 | 93.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 15 | $2,775 | $2,138 | 77.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 70 | 165 | $4,950 | $1,596 | 32.2% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 35 | 38 | $1,900 | $1,500 | 79.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 89 | 331 | $4,965 | $1,065 | 21.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 13 | 18 | $2,610 | $959.24 | 36.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 14 | 17 | $1,692 | $700.27 | 41.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 17 | 34 | $680.00 | $551.48 | 81.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 53 | 480 | $1,200 | $402.92 | 33.6% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2022 | 36 | 44 | $1,100 | $319.50 | 29.0% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2022 | 26 | 58 | $580.00 | $265.04 | 45.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 17 | 18 | $1,080 | $156.49 | 14.5% |
| 81002 | Urinalysis, manual test | Office | 2022 | 33 | 42 | $420.00 | $144.41 | 34.4% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 38 | 126 | $630.00 | $53.41 | 8.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 312 | 1,143 | $108,121 | $70,577 | 65.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 217 | 358 | $49,705 | $29,473 | 59.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 174 | 174 | $25,055 | $22,787 | 90.9% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 31 | 34 | $9,550 | $7,605 | 79.6% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 224 | 226 | $7,910 | $6,757 | 85.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 41 | 56 | $7,900 | $4,484 | 56.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 28 | $5,160 | $3,799 | 73.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 225 | 227 | $6,810 | $3,675 | 54.0% |
About Dr. Pradip Vyas, M.D
Dr. Pradip Vyas, M.D is a Internal Medicine healthcare provider based in Troy, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023129103.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pradip Vyas, M.D has received a total of $244.73 in payments from pharmaceutical and medical device companies, with $14.81 received in 2023. These payments were reported across 6 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($244.73).
As a Medicare-enrolled provider, Vyas has provided services to 6,663 Medicare beneficiaries, totaling 12,838 services with total Medicare billing of $602,649. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Troy, OH
- Active Since 08/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023129103
Products in Payments
- TRELEGY ELLIPTA (Drug) $187.82
- FREESTYLE LIBRE (Device) $21.81
- Otezla (Drug) $20.29
- MOUNJARO (Drug) $14.81
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Troy
Dr. Neil Fraser, Md, MD
Internal Medicine — Payments: $180,276
Dr. John Calado, Do, DO
Internal Medicine — Payments: $152,221
Michael Doyle, Md, MD
Internal Medicine — Payments: $85,884
Dr. Jay Sandberg, D.o, D.O
Internal Medicine — Payments: $28,867
Dr. Mohammed Kabir, Md, MD
Internal Medicine — Payments: $26,648
Dr. Noor Bunney, Md, MD
Internal Medicine — Payments: $21,394